Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00827008 · ClinicalTrials.gov registry record · Phase 3
Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus
A Phase 3 study, sponsored by Merz Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 821
- Enrollment target
NCT00827008 is a Phase 3 study that was terminated before completion, run by Merz Pharmaceuticals. The registered enrollment target is 821 participants.
The verdict
NCT00827008, a Phase 3 study, was terminated before completion, sponsored by Merz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 821 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramexane mesylate in the long-term treatment of subjective tinnitus after a completed double-blind randomized placebo controlled study
Interventions
- DRUG Neramexane mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 821 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00827008
The ClinicalTrials.gov registry entry for NCT00827008 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 821 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neramexane mesylate is the first listed.
NCT00827008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00827008 about?
NCT00827008 is a clinical study titled "Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus". The purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramexane mesylate in the long-term treatment of subjective tinnitus after a completed double-blind randomized placebo controlled study
What is the current status of trial NCT00827008?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 821 participants. The study started on 2009-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00827008?
The interventions under investigation include: Neramexane mesylate (DRUG).
Who is sponsoring clinical trial NCT00827008?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.